Wednesday, November 11, 2026
ExploreSearch
Via News
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
News articleCB Insights

14 repeat founders building agentic commerce

View original at cbinsights.com
CB Insights - Enterprise Ai Title: 14 repeat founders building agentic commerce Date: 2026-10-23 15:12 Source: https://www.cbinsights.com/research/14-repeat-founders-building-agentic-commerce/ <p><span style="font-weight: 400;">Some of the founders who helped build online shopping are now preparing for AI agents to do…
Opening lines of the source · CB Insights · short snapshot — read the full document at the original

What we drew from this source

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • Agents will take over routine, repeat purchases first, particularly groceries, household essentials and personal care, where convenience, price and product preference matter more than shopping experience.

    60% confidence

  • CB Insights profiled 14 repeat founders across 9 agentic commerce companies and has 60+ repeat founders in agentic commerce in its data.

    60% confidence

  • Grocery lit up first as meal planners used AI, followed by electronics, pet and sporting goods; auto parts and automotive lag.

    60% confidence

  • Agents are best suited to use the infrastructure humans already use (websites, logins, wallets, checkout flows) rather than integrating into APIs.

    60% confidence

  • 12 of 14 repeat founders, across 7 companies, joined Mastercard Start Path's Agentic Commerce & Services program in September; only COFE Tech and Azoma raised outside it.

    60% confidence

  • 4 of the 9 companies (Skyfire, Nevermined, PayOS, SolvaPay) build payment or identity infrastructure for agents; Skyfire and Nevermined route agent payments over card networks as well as stablecoins.

    60% confidence

Cited in these Via News reports

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Biotech Catalyst Wave: Late-2026 Clinical Readouts, PDUFA Dates and Capital Restructuring
A dense cluster of Q4 2026 to Q1 2027 clinical and regulatory catalysts spans hepatitis delta (Vir's ECLIPSE/SOLSTICE), hypertension and sleep apnea (Mineralys' lorundrostat, PDUFA 2026-12-22), severe hypertriglyceridemia (plozasiran), oncology (ivonescimab BLA, PDUFA 2026-11-14) and gene therapy (Krystal). Positive data flow from AASLD and AHA presentations is offset by cost-cutting guidance, milestones slipping into 2027, and a delisting process that signals capital-market stress for some issuers. Near-term value hinges on binary FDA decisions and Phase 3 topline readouts in Q1 2027.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
Ford Motor Company
Both facts give cash for Ford Motor Company at the same point in time (2025-12-31; FY 2025 year-end and Q4 2025 year-end are the same date). Both are labelled USD, but the values are 23,356,000,000 and 23.356, which cannot both be true in USD. The two numbers agree once the second is read as billions (23.356 bn = 23,356,000,000), so the economic content is consistent and the conflict is a unit/scale error in the Q4 2025 record. The period is not the reason for the conflict: a Q4 and an FY figure at the same year-end date should match.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,995
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,995 facts checked against source5,564 source documents archived
Query this data → isubstrate.com
14 repeat founders building agentic commerce — Source | Via News | Via News